Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
about
Linking epithelial-to-mesenchymal-transition and epigenetic modificationsCharacterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patientsCase report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapiesMolecular profiling of hepatocellular carcinomas by cDNA microarray.High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survivalNovel perspective: focusing on the X chromosome in reproductive cancers.Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicityCancer testis antigens--their importance in immunotherapy and in the early detection of cancer.Programmed death-1 checkpoint blockade in acute myeloid leukemia.High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma.Detection of MAGE and SSX gene expressions by RT-nested PCR using common primers in head and neck cancer.Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeuticsImmunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues.Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma.Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.
P2860
Q26824575-987FAB0C-FFDE-456C-948B-939A1E23864FQ30358114-3358ACB4-CA51-438A-BC23-9751EB03D29BQ30834078-66661A6B-006C-4372-B963-8C43E8A631CCQ34605680-33C2B734-73D1-48F2-A97E-7FE1119A9F21Q35144956-42F33724-6515-473A-BC6C-9C7D5428CCCDQ35553879-B7FC275A-3E16-4C13-A326-6DEA09C0832FQ35733359-F1D0DCA9-BD21-4572-8AAE-D1EC2AE1E60EQ36415124-4F42880F-B543-4E20-BF34-2EF1522615B7Q36425935-DEFEF682-0128-456D-A627-3B22CDA367E8Q36652124-3CD047E2-4147-47C5-A4BC-507DF63AE7C1Q36782607-7F169596-3206-4819-AFD9-A000340FED66Q37165645-FEE1813A-B40A-4664-8E1E-207DEE771BC7Q37785109-AF0C50E9-B7DC-4AC2-BBD7-81992D4A7D96Q40484689-0285121D-D59F-481D-8AAF-64DFB23BF74DQ45811544-FDDCDE0B-5059-4036-BC12-69C77AD3171EQ47199295-18A27F6F-17CC-401B-8157-3ECA869D1830
P2860
Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@ast
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@en
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@nl
type
label
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@ast
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@en
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@nl
prefLabel
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@ast
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@en
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@nl
P2860
P356
P1476
Cancer-testis antigens: promis ...... antineoplastic immunotherapy.
@en
P2093
Bela Bodey
P2860
P304
P356
10.1517/14712598.2.6.577
P407
P577
2002-08-01T00:00:00Z